Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reboxetine and AD128 crossover study in obstructive sleep apnoea
ACTRN12620000662965Phase 2Completed
- Sponsor
- Flinders University
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of reboxetine and reboxetine + oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Flinders University. Primary endpoint: Apnoea/hypopnoea index. Started Jun 2020; status: completed.
02
Drugs
reboxetinereboxetine + oxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12620000662965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000662965.